|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's Range||85.14 - 90.74|
|52 Week Range||71.42 - 163.43|
|Beta (5Y Monthly)||2.35|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 19, 2020 - Feb 24, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||142.94|
A handful of sickle cell disease treatments and CAR-T therapies that treat cancer have been approved by the Food and Drug Administration in recent years, but a new crop of investigational therapies that would grow those markets is exciting investors.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing more than 750 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of September […]
Bluebird bio is set to start earning money from drug sales next year, and SVB Leerink analyst Mani Foroohar is increasing his price target on the stock.
bluebird bio and BMS announce updated results from the ongoing Phase 1 study (CRB-402) of bb21217 in Relapsed and Refractory Multiple Myeloma at ASH
bluebird bio, Inc. announced new data from ongoing studies of LentiGlobin™ gene therapy for β-thalassemia at the 61st ASH Annual Meeting.
bluebird (BLUE) and partner Bristol-Myers report positive top-line results from a phase II study on idecabtagene vicleucel in patients with relapsed and refractory multiple myeloma.
Stocks slipped slightly on Monday as investors work off some of Friday's jobs report rally and as trade-war headlines continue to pop up. Let's look at a few top stock trades as we kick off the week. Top Stock Trades for Tomorrow No. 1: Chewy (CHWY)Source: Chart courtesy of StockCharts.comChewy (NYSE:CHWY) is set to report earnings after the close Monday, as are our Top Trades No. 2 and 3.Over the last few trading sessions, CHWY stock has fought hard to break out over downtrend resistance (blue line). To its credit, Chewy stock has done a good job holding up over this mark, although it struggled in Monday's session.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAfter the company reports after the close, it's vital that the stock doesn't go on to make new lows below $21.68. If it does, it puts $20 -- and possibly the teens -- on the table. Ideally though, CHWY will hold up over the 20-day moving average at $23.57, as well as downtrend resistance. * 7 Overlooked Value Stocks to Buy That Will Shine in 2020 On the upside, let's see if CHWY can clear some of the clutter near current levels. Specifically, let's see if it can clear the 50-day moving average and the $25 level. Above that puts the 78.6% retracement just below $26 on the table. Moving above all of these levels puts the declining 100-day moving average near $28 on the table. Top Stock Trades for Tomorrow No. 2: Toll Brothers (TOL)Source: Chart courtesy of StockCharts.comI have routinely highlighted Toll Brothers (NYSE:TOL) as a relative strength leader. The stock has a pattern of ripping to new highs, consolidating its gains and rallying to new highs again.Can it do it again on earnings?TOL stock is trying to break out over the $41.50 level. See if it can get above and more importantly, stay above this level after its post-earnings reaction. If it can, a breakout maybe in the making.On a decline, see where support comes into play. Can TOL hold its 20-day and 50-day moving averages near $40? How about uptrend support (blue line) near $39.50? Falling below the pattern puts $38.50 on the table. Below that and the 200-day moving average is possible. Top Stock Trades for Tomorrow No. 3: Stitch Fix (SFIX)Source: Chart courtesy of StockCharts.comStitch Fix (NASDAQ:SFIX) shares made an impressive move Monday, breaking out over $24. Of course, the whole move could be for naught, depending on the post-earnings reaction.On a pullback, it would be ideal for SFIX stock to hold this $24 breakout level as support. But given SFIX's history of volatility, that's also unlikely. So on the downside, let's see if $22 can hold as support. There it has short-term uptrend support (blue line), as well as the 100-day moving average. Further, its 50-day moving average sits at $22.28. Below this area could put $18 on the table.On the upside, let's see if SFIX can reclaim its 50% retracement near $26.90. Above that puts the 61.8% retracement on the table. Top Stock Trades for Tomorrow No. 4: Bluebird bio (BLUE)Source: Chart courtesy of StockCharts.comIt has been a tough run for bluebird bio (NASDAQ:BLUE), as highlighted by Monday's 2.7% decline. In late November, BLUE broke out over downtrend resistance (blue line), but found $85 and the 50-day moving average to be resistance.After Monday's pullback, the backside of that downtrend mark buoyed the share price. For bulls, the setup is now simple.On the downside, prior downtrend resistance and the $72 level have to hold as support. On the upside, bulls need to reclaim $85 and the 50-day moving average. Top Stock Trades for Tomorrow No. 5: Shopify (SHOP)Source: Chart courtesy of StockCharts.comShopify (NASDAQ:SHOP) has been getting a lot of attention lately and deservedly so.Again, keep this one as simple as you can. Recent resistance has come into play at $375. Above it opens the door to $400. At the same time, recent support has come into play near $360. Below it puts $340 on the table. Below that and the 50-day moving average will be key.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Energy Stocks That Are Still Worth Buying In 2020 * 7 Strong Stocks to Buy That Won Q3 Earnings * 5 Safety Stocks to Buy Without Trade War Exposure The post 5 Top Stock Trades for Tuesday: CHWY, SFIX, SHOP appeared first on InvestorPlace.
Shares took off Monday morning after the company reported data at a medical conference over the weekend that relieved investor anxiety over the company’s experimental cancer drug ide-cel.
bluebird bio Presents New Data from Ongoing Phase 1/2 HGB-206 Study of LentiGlobin™ Gene Therapy for Sickle Cell Disease (SCD) at ASH Annual Meeting
(Bloomberg) -- An experimental therapy from Bluebird Bio Inc. and Bristol-Myers Squibb Co. benefited more than 80% of patients nearing death from an advanced form of blood cancer in a pivotal study, clearing a hurdle in its path to U.S. approval.A single high-dose infusion of the personalized medicine known as bb2121 generated a response in 44 of 54 patients with multiple myeloma, including 19 who had a complete response, the companies said in a statement Friday. Patients went a median of 11.3 months before the cancer progressed, topping expectations that it needed to stop the disease for at least six months to gain approval from the U.S. Food and Drug Administration.Bluebird shares briefly jumped in late trading on Friday before surrendering most of their gains. The recently-issued CVR given in connection with the closing of Bristol-Myers’ deal with Celgene, known by the ticker BMY-R, rose 8.3%.The companies divulged the findings on the eve of the American Society of Hematology’s annual meeting in Orlando, Florida, where GlaxoSmithKline Plc., Regeneron Pharmaceuticals Inc. and Bristol’s own Celgene unit will present data on competing approaches. Cambridge, Massachusetts-based Bluebird and New York-based Bristol-Myers are scheduled to give an update on their next-generation therapy, bb21217, on Monday, while hotly anticipated results from competitor Johnson & Johnson’s Nanjing Legend Biotech-partnered therapy will take the spotlight that morning.The depth and the durability of the data “puts us in very good stead around any of the antibodies as well as other gene therapies,” Bluebird Chief Executive Officer Nick Leschly said. “We feel quite good about it, and that’s why we’re sprinting toward submission and driving toward earlier lines of therapy.”Positive results from the study, dubbed KarMMa, could lead to the first approval of the approach called CAR-T for patients with multiple myeloma, a deadly form of cancer found in white blood cells, wrote Raju Prasad, an analyst at William Blair, in a note. A response rate greater than 80% that can hold off the disease for at least 11 months would be well-received by doctors who might otherwise be wary of potential high costs and an aggressive approach, said Yaron Werber, an analyst at Cowen & Co.The approach known as CAR-T is already approved for a hard-to-treat form of pediatric leukemia and diffuse large B cell lymphoma, both blood cancers that are much less common than the multiple myeloma, which is diagnosed in about 30,000 Americans each year. Bluebird and Bristol’s therapy involves removing infection-fighting T cells from the blood, altering them to recognize a protein known as BCMA that is found in multiple myeloma cells, then putting them back into the patient to kill the cancer.(Updates with stock-price movement in third paragraph)\--With assistance from Tatiana Darie.To contact the reporters on this story: Bailey Lipschultz in New York at firstname.lastname@example.org;Michelle Fay Cortez in Minneapolis at email@example.comTo contact the editors responsible for this story: Catherine Larkin at firstname.lastname@example.org, Mark Schoifet, Timothy AnnettFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
BMS and bluebird bio Announce Positive Top-line Results from the Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma
bluebird bio, Inc. (BLUE) today announced that the company will host a live webcast on December 9, 2019 at 8:00 p.m. ET to review clinical data presented at the 61st American Society of Hematology Annual Meeting and Exposition. To access the live webcast of bluebird bio’s presentation, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcast will be available on the bluebird bio website for 90 days following the event.
Global Blood's (GBT) Oxbryta wins the FDA nod to address sickle cell disease in patients aged 12 years and above. The approval comes three months ahead of schedule.
CRISPR Therapeutics and Vertex Pharmaceuticals released the first data from their early-stage trial testing the safety and effectiveness of a potential cure for the genetic blood disorders sickle cell disease and beta thalassemia.
bluebird bio, Inc. (BLUE) and Forty Seven, Inc. (FTSV) announced today that they have entered into a research collaboration to pursue clinical proof-of-concept for Forty Seven’s novel antibody-based conditioning regimen, FSI-174 (anti-cKIT antibody) plus magrolimab (anti-CD47 antibody), with bluebird’s ex vivo lentiviral vector hematopoietic stem cell (LVV HSC) gene therapy platform. This collaboration will focus on a conditioning approach aimed to deliver reduced toxicity and will initially target diseases that have the potential to be corrected with transplantation of autologous gene-modified blood-forming stem cells.
Luspatercept is one of the first treatments for beta thalassemia, a blood disorder being targeted by multiple local companies.
Massachusetts is home to 36 of the 500 companies making this year’s ranking, with three local firms making the top 100 — including the No. 2 spot.
Updated safety and efficacy results from ongoing Phase 1 CRB-402 study of bb21217 in relapsed/refractory multiple myeloma
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...